Fortrea (FTRE) – Research Analysts’ Weekly Ratings Updates

Fortrea (NASDAQ: FTRE) recently received a number of ratings updates from brokerages and research firms:

• 7/21/2026 – Fortrea was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Fortrea had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Fortrea had its price target raised by Mizuho from $13.00 to $16.00. They now have a “neutral” rating on the stock.
• 7/13/2026 – Fortrea was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/6/2026 – Fortrea was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/5/2026 – Fortrea was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/27/2026 – Fortrea was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/24/2026 – Fortrea had its price target raised by Barclays PLC from $16.00 to $18.00. They now have an “equal weight” rating on the stock.

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.